Plasma-SeqSensei™ Thyroid Cancer RUO Kit
Plasma-SeqSensei™ Thyroid Cancer RUO Kit
- Highly sensitive down to 0.07 % MAF
- Able to detect 7 MM with 95 % confidence across all mutations (absolute quantification)
- High flexibility of between 2 - 16 samples/run
- Fast TAT (2 days)
- Convenient software
The Plasma-SeqSensei™ (PSS) Thyroid Cancer RUO (research use only) Kit detects mutations in circulating tumour DNA (ctDNA) from plasma in patients with thyroid cancer.
The kit uses next generation sequencing and covers the BRAF and NRAS genes with hotspot mutations:. These gene mutations are associated with more rapid cancer growth and worse prognosis. [1-2]
Differentiated (papillary (PTC) and follicular TC (FTC)) make up more than 90% of thyroid malignancies (BRAF with >60% and NRAS with 6-57% frequency of known somatic mutations). [3]
For the configuration of the Plasma-SeqSensei™ Thyroid RUO kits, two key cancer genes were selected after comparison of mutation frequencies using the COSMIC (Catalogue of Somatic Mutation in Cancer) and cBioPortal for cancer genomics databases.
Mutation frequencies are listed in the table below:
Thyroid cancer
| COSMIC [4] | cBioPortal [5] | |
| BRAF | 51.8% | 60.0% |
| NRAS | 8.2% | 8.0% |
Most frequent mutations detected by Plasma-SeqSensei™ Thyroid Cancer RUO panel:
| Gene ID | Most frequent mutations in thyroid cancer |
| BRAF | V600E, K601E, V600_K601delinsE |
| NRAS | Q61R, Q61K, Q61L |
Plasma-SeqSensei™ Thyroid RUO Kit is intended for research use only. Diagnostic use is not supported.
References
- Huang et al. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China. Diagnostic Pathology 14(74), 1-10, 2019.
- Perdana et al. Clinical Utility of BRAF, NRAS, and TERT Promoter Mutation in Preoperative Thyroid Fine-Needle Aspiration Biopsy: A Diagnostic Study From Dharmais Cancer Hospital. Asian Pac J Cancer Prev 21(11), 3267-3277, 2020.
- Prete et al. Update on Fundamental Mechanisms of Thyroid Cancer. Frontiers in Endocrinology 11(102), 1-10, 2020.
- https://cancer.sanger.ac.uk/cosmic
- https://www.cbioportal.org/
Sysmex Europe SE
Bornbarch 1
22848 Norderstedt
Germany
+49 (40) 527 26 0
+49 (40) 527 26 100
Product documents
Regulatory documents
Regulatory documents, such as Instructions for Use, can be accessed with a valid My Sysmex login:
Go to My Sysmex
